| Business Summary | | Vasomedical,
Inc.
is
engaged
in
the
research,
development
and
commercialization
of
systems
and
equipment
designed
to
provide
non-invasive
treatment
of
patients
with
cardiovascular
disease.
The
Company's
lead
product,
its
Enhanced
External
Counterpulsation
(EECP)
system,
is
a
patented
microprocessor-based
device
that
delivers
a
retrograde
arterial
pressure
wave
to
the
heart,
increasing
coronary
perfusion
and
reducing
ventricular
afterload.
EECP
therapy
offers
dramatic
relief
of
symptoms
to
angina
sufferers
who
no
longer
respond
to
medication
or
are
poor
candidates
for
invasive
revascularization
procedures
such
as
bypass
surgery
or
balloon
angioplasty.
This
system
is
marketed
worldwide
to
hospitals,
clinics
and
other
cardiac
healthcare
providers. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Vasomedical
is
engaged
in
the
commercialization
of
the
enhanced
external
counterpulsation
(EECP)
system,
a
computer-based
medical
device
for
the
non-invasive,
atraumatic
treatment
of
patients
with
coronary
artery
disease.
For
the
fiscal
year
ended
5/31/01,
revenues
totaled
$27.5
million,
up
from
$13.7
million.
Net
income
applicable
to
Common
totaled
$11.7
million,
up
from
$1.6
million.
Results
reflect
increased
acceptance
of
the
EECP
systems
and
higher
tax
benefits. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| Abraham Cohen, 64 Chairman | -- | -- | D. Michael Deignan, 56 Pres,
CEO, Director | $75K | -- | John Hui, 54 Sr.
VP, R&D and Manufacturing | 629K | $489K | Joseph Giacalone, 36 Sec.
and Treasurer | 1.5M | 1.4M | Dollar
amounts are as of 31-May-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|